Regenerative medicines can be defined as ways for regrowing, replacing injured cells, organs, or tissues, with medication covering the production of artificial organs, tissue engineering, and therapeutic stem cells, as well as the production of artificial organs. Regenerative orthopedics drugs can aid in the mending of damaged tissues as well as the reduction of discomfort and pain associated with musculoskeletal disorders. Stem cells, plasma-rich sources, biological tissues, and bone marrow can be used to create regenerative medicine. Orthopedic regenerative drugs aid in the recovery of ligament, tendon, bone, spinal disc, muscle, cartilage, and other musculoskeletal tissues injuries. These regenerative drugs can repair organs and tissues that have been damaged due to aging or accidents. Regenerative medicines which include stem cells therapy and tissue engineering can help in transplanting biologicals tissues.
Global Orthopedic Regenerative Medicine Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has hampered the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, according to the article published by The National Center of Biotechnology Information (NCBI), France’s Department of Public Health, stated about the impact of COVID-19 on the Cell and Gene Therapy industry (CGT) as On an emergency basis, all CGT developers shifted their efforts to producing therapeutics and vaccines for COVID-19.The developments required for cell and gene therapies. As a result, all the important factors required in Cell and Gene Therapy industry (CGT) got hampered such as funding for research and development, manufacturing resilience, value-based pricing, innovative developments which affected the market of cell and gene therapy.
Moreover, the COVID-19 pandemic has negatively impacted the ongoing clinical trials of various new drug molecules, treatments, and therapies, which is expected to affect the global orthopedic regenerative medicine market growth. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the commencement of clinical trials due to restrictions for traveling, unavailability of trial site staff, investigational product availability, and others factors required for approvals and designation from regulatory authorities.
The global orthopedic regenerative medicine market is estimated to be valued at US$ 7,774.7 Mn in 2021 and is expected to exhibit a CAGR of 10.8% over the forecast period (2021-2028).
Figure 1: Global Orthopedic Regenerative Medicine Market Share, (%), Analysis, By Treatment Type, 2021
Market players are indulged in receiving approvals for the products indicated for the treatment of orthopedic diseases, which is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period.
Increasing approvals from the regulatory authorities is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, on July 22, 2019, Personalized Stem Cells Inc., which provides services of autologous adipose derived stem cells, received approval from the U.S. Food and Drug Administration (FDA) for treatment of osteoarthritis with stem cells. For treatment, Phase 1 clinical trials were conducted by providing Investigational Biologic Product (IBP) i.e. PSC- 01, which is a form of autologous cellular therapy developed from enzymatic processing of lipoaspirate to yield adipose derived stromal vascular fraction (SVF) cells.
Increasing product launches by the market players for the treatment of orthopedic diseases is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period
Market players are involved in developing and launching products for the treatment of orthopedic diseases. This is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, on January 1, 2020, Royal Biologics, which is a company of regenerative cellular technology has launched MAGNUS, a cellular bone allograft with Dimethyl Sulfoxide (DMSO) free cryoprotectant. This MAGNUS cellular bone allograft will help in bone formation and induce the activity of osteoblasts and osteoclasts which demonstrate in rapid healing of defective bone.
Orthopedic Regenerative Medicine Market Report Coverage
||Market Size in 2021:
US$ 7,774.7 Million
|Historical Data for:
||2018 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
US$ 15,891.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Treatment Type: Stem Cell Therapy (Allogeneic Bone, Autogenic Bone, Bone Grafting), Plasma Based Therapy, Tissue Engineering (Allograft)
- By Disease Indication: Osteoarticular Diseases, Rheumatoid Arthritis, Ligament Injuries, Bursitis, Osteoporosis
- By End User: Hospitals and clinics, Orthopedic specialty centers, Others
Ortho Regenerative Technologies Inc., Personalized stem cells Inc., Anika Therapeutics Inc., Arthrex Inc., Baxter International Inc., Conmed Corporation, Aziyo Biologics, Curasan Inc., Swiss biomed Orthopedics AG, Octane Medical Inc., Stryker Corporation, Carmell Therapeutics Corporation, Zimmer Holdings, Smith & Nephew plc., and NuVasive Inc.
- Increasing product launches and approvals
- Increasing research and development activities
|Restraints & Challenges:
- Limitations for treatments from regulatory authorities
- Post treatment side effects and failures
Global Orthopedic Regenerative Medicine Market – Restraints
Regulatory authorities’ limitations and directions for the treatment of orthopedic diseases is expected to hamper the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, on January 27, 2021, an article published in the National Center for Biotechnology Information (NCBI) about future of regenerative medicines where limitation for therapy was mentioned such as aged related muscular degeneration where regeneration of cells is necessary for healing the injury but due to age factor regeneration may not be helpful, another factor which may affect the treatment is cell product variability of donors stem cells.
The post treatment side effects due to regenerative medicines is expected to hamper the growth of the orthopedic regenerative medicine market over the forecast period. For instance, on June 8, 2021, an article published by International Society for Stem Cell Research (ISSCR) stated about unproven stem cells interventions like bone marrow and bone grafts, which are not approved by regulatory authorities, has shown adverse effects such as nausea, vomiting, bacterial infections, and graft failure from unproven stem cells which affects the funding and clinical trials recruitments and increases the burden on regulatory agencies.
Global Orthopedic Regenerative Medicine Market – Regional Analysis
On the basis of region, the global orthopedic regenerative medicine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold a dominant position during the forecast period, owing to the increasing grants and approvals for products by regulatory authorities in region. For instance, on April 27, 2020, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation which is expedited review of investigational drug for serious or life threatening condition , has approved to Carmell Therapeutics, which works on patent-based technology and manufacturer of biologically active materials based in the U.S., received grant for Bone Healing Accelerant (BHA) to treat the tibia fractures and in December, BHA got approved by the U.S. FDA as Investigational New Drug (IND). By receiving BHA grants and approvals, the benefits of receiving Biologic License Application (BLA) approval will be provided through these approvals and grants.
Furthermore, Europe is also estimated to witness a significant growth in the global orthopedic regenerative medicine market, owing to the increasing product distributions in Europe region by the market players and research institute. For instance, on April 12, 2021, Curasan AG, which is a manufacturer of products for dental bone grafting and tissue regenerated products, announced distribution network of their products in Europe region with two partners, Silesia Dental ,a company that provides dental products , which will help in providing dental products of Curasan AG and Implants Diffusion International SARL (IDI) which develops new products for implantology, they intend to sell Curasan AG dental products as a distributor.
Figure 2: Global Orthopedic Regenerative Medicine Market (US$ Mn), by Region, 2021
Global Orthopedic Regenerative Medicine Market – Competitive Landscape
Major players operating in the global orthopedic regenerative medicine market include Ortho Regenerative Technologies Inc., Personalized stem cells Inc. , Anika Therapeutics Inc., Arthrex Inc., Baxter International Inc., Conmed Corporation, Aziyo Biologics, Curasan Inc., Swiss biomed Orthopedics AG, Octane Medical Inc., Stryker Corporation, Carmell Therapeutics Corporation, Zimmer Holdings, Smith & Nephew plc., and NuVasive Inc.